Amneal Pharmaceuticals Inc
AMRX12.930USD
+0.060+0.47%
Market hours （ET）Quotes delayed by 15 min
4.06BMarket Cap
725.59P/E TTM
More Details of Amneal Pharmaceuticals Inc Company
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Amneal Pharmaceuticals Inc Info
Ticker SymbolAMRX
Company nameAmneal Pharmaceuticals Inc
IPO dateNov 18, 2009
CEOPatel (Chintu)
Number of employees8100
Security typeOrdinary Share
Fiscal year-endNov 18
Address400 Crossing Boulevard, 3rd Floor
CityBRIDGEWATER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08807
Phone19089473120
Websitehttps://amneal.com/
Ticker SymbolAMRX
IPO dateNov 18, 2009
CEOPatel (Chintu)
Company Executives of Amneal Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
--
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
191.40K
--
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%
Mr. Chirag Patel
Mr. Chirag Patel
President, Co-Chief Executive Officer, Co-Founder, Director
President, Co-Chief Executive Officer, Co-Founder, Director
--
--
Mr. Ted Nark
Mr. Ted Nark
Independent Director
Independent Director
--
--
Mr. Paul M. Meister
Mr. Paul M. Meister
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John J. Kiely
Mr. John J. Kiely
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
--
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
191.40K
--
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Oral solid
178.26M
24.60%
Distribution
99.66M
13.76%
Central Nervous System
83.42M
11.51%
Other dosage forms
68.19M
9.41%
Auto-injector
66.59M
9.19%
Other
228.38M
31.52%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oral solid
178.26M
24.60%
Distribution
99.66M
13.76%
Central Nervous System
83.42M
11.51%
Other dosage forms
68.19M
9.41%
Auto-injector
66.59M
9.19%
Other
228.38M
31.52%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Patel (Tushar Bhikhubhai)
15.45%
Patel (Chintu)
8.15%
Patel (Dipan)
7.58%
Patel (Chirag K)
7.04%
Akram (Mahesh)
6.54%
Other
55.24%
Shareholders
Shareholders
Proportion
Patel (Tushar Bhikhubhai)
15.45%
Patel (Chintu)
8.15%
Patel (Dipan)
7.58%
Patel (Chirag K)
7.04%
Akram (Mahesh)
6.54%
Other
55.24%
Shareholder Types
Shareholders
Proportion
Individual Investor
46.38%
Investment Advisor
19.36%
Investment Advisor/Hedge Fund
11.79%
Hedge Fund
11.60%
Private Equity
3.92%
Research Firm
1.93%
Pension Fund
0.27%
Bank and Trust
0.19%
Family Office
0.03%
Other
4.54%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
448
154.72M
55.65%
+68.38K
2025Q3
455
154.66M
56.61%
+8.55M
2025Q2
432
145.89M
53.25%
+6.99M
2025Q1
416
138.78M
50.16%
-18.42M
2024Q4
398
129.01M
49.64%
-14.17M
2024Q3
380
143.02M
47.07%
+6.97M
2024Q2
372
135.82M
34.71%
+37.56M
2024Q1
356
97.40M
32.81%
-3.83M
2023Q4
348
89.35M
29.61%
+7.08M
2023Q3
338
82.03M
56.21%
+4.32M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Patel (Tushar Bhikhubhai)
48.58M
15.47%
-5.00M
-9.33%
Mar 14, 2025
Patel (Chintu)
25.62M
8.16%
+351.47K
+1.39%
Mar 14, 2025
Patel (Dipan)
23.83M
7.6%
--
--
Mar 14, 2025
Patel (Chirag K)
22.13M
7.05%
--
--
Aug 06, 2025
Akram (Mahesh)
20.56M
6.55%
-6.30M
-23.45%
Mar 31, 2025
The Vanguard Group, Inc.
17.49M
5.57%
+1.78M
+11.34%
Jun 30, 2025
Rubric Capital Management LP
11.71M
3.73%
+974.36K
+9.08%
Jun 30, 2025
TPG Capital, L.P.
12.33M
3.93%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
10.64M
3.39%
-499.58K
-4.49%
Jun 30, 2025
Citadel Advisors LLC
5.62M
1.79%
-1.87M
-24.92%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Pharmaceuticals ETF
3.08%
State Street SPDR S&P Pharmaceuticals ETF
2.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2%
Invesco Dorsey Wright Healthcare Momentum ETF
0.99%
Invesco Dorsey Wright SmallCap Momentum ETF
0.83%
First Trust NASDAQ Pharmaceuticals ETF
0.78%
First Trust Small Cap Growth AlphaDEX Fund
0.72%
iShares U.S. Pharmaceuticals ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.48%
WisdomTree US SmallCap Fund
0.36%
View more
Invesco Pharmaceuticals ETF
Proportion3.08%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.99%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.83%
First Trust NASDAQ Pharmaceuticals ETF
Proportion0.78%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.72%
iShares U.S. Pharmaceuticals ETF
Proportion0.68%
ProShares Ultra Nasdaq Biotechnology
Proportion0.48%
WisdomTree US SmallCap Fund
Proportion0.36%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Amneal Pharmaceuticals Inc?
The top five shareholders of Amneal Pharmaceuticals Inc are:
Patel (Tushar Bhikhubhai) holds 48.58M shares, accounting for 15.47% of the total shares.
Patel (Chintu) holds 25.62M shares, accounting for 8.16% of the total shares.
Patel (Dipan) holds 23.83M shares, accounting for 7.60% of the total shares.
Patel (Chirag K) holds 22.13M shares, accounting for 7.05% of the total shares.
Akram (Mahesh) holds 20.56M shares, accounting for 6.55% of the total shares.
Patel (Tushar Bhikhubhai) holds 48.58M shares, accounting for 15.47% of the total shares.
Patel (Chintu) holds 25.62M shares, accounting for 8.16% of the total shares.
Patel (Dipan) holds 23.83M shares, accounting for 7.60% of the total shares.
Patel (Chirag K) holds 22.13M shares, accounting for 7.05% of the total shares.
Akram (Mahesh) holds 20.56M shares, accounting for 6.55% of the total shares.
What are the top three shareholder types of Amneal Pharmaceuticals Inc?
The top three shareholder types of Amneal Pharmaceuticals Inc are:
Patel (Tushar Bhikhubhai)
Patel (Chintu)
Patel (Dipan)
Patel (Tushar Bhikhubhai)
Patel (Chintu)
Patel (Dipan)
How many institutions hold shares of Amneal Pharmaceuticals Inc (AMRX)?
As of 2025Q4, 448 institutions hold shares of Amneal Pharmaceuticals Inc, with a combined market value of approximately 154.72M, accounting for 55.65% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.96%.
What is the biggest source of revenue for Amneal Pharmaceuticals Inc?
In FY2025Q2, the Oral solid business generated the highest revenue for Amneal Pharmaceuticals Inc, amounting to 178.26M and accounting for 24.60% of total revenue.
